GMVD · G Medical Innovations Holdings Ltd. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 |
|---|---|---|
| Revenue | $4.42M | $4.90M |
| Cost of Revenue | $113.0K | $398.0K |
| Gross Profit | $784.0K | $667.0K |
| R&D | $2.29M | $1.31M |
| SG&A | $20.61M | $11.65M |
| Total Operating Expenses | - | - |
| D&A | $667.0K | $1.16M |
| Operating Income | ($22.11M) | ($12.30M) |
| Interest Expense | $9.38M | $750.0K |
| Income Tax | $16.0K | ($18.0K) |
| Net Income | ($12.69M) | ($12.69M) |
| EPS - Basic | ($34.17) | ($1.70) |
| EPS - Diluted | ($34.17) | ($1.70) |
Balance Sheet
| Line item | FY 2022 | FY 2021 |
|---|---|---|
| Cash & Equivalents | $295.0K | $6.03M |
| Accounts Receivable | $441.0K | $1.42M |
| Inventory | $292.0K | $90.0K |
| Accounts Payable | - | - |
| Current Assets | $1.99M | $3.13M |
| Total Assets | $4.83M | $10.52M |
| Current Liabilities | $9.11M | $7.90M |
| Long-term Debt | - | - |
| Total Liabilities | - | - |
| Stockholders' Equity | ($4.57M) | ($2.95M) |
| Retained Earnings | ($115.26M) | ($90.63M) |
Cash Flow
| Line item | FY 2022 | FY 2021 |
|---|---|---|
| Operating Cash Flow | ($18.48M) | ($4.65M) |
| Investing Cash Flow | ($2.12M) | ($455.0K) |
| Financing Cash Flow | $14.86M | $5.38M |
| CapEx | - | - |
| Free Cash Flow | - | - |
Ratios
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Profitability | ||
| Gross margin | 17.7% | 13.6% |
| Operating margin | -500.3% | -251.0% |
| EBITDA margin | -485.2% | -227.3% |
| Net margin | -287.1% | -258.9% |
| Free cash flow margin | - | - |
| FCF / Net income | - | - |
| R&D / Revenue | 51.9% | 26.8% |
| SG&A / Revenue | 466.2% | 237.8% |
| Effective tax rate | - | - |
| Return on assets | -263.0% | -120.6% |
| Return on equity | 277.6% | 430.2% |
| Return on invested capital | - | - |
| Liquidity | ||
| Current ratio | 0.22 | 0.40 |
| Quick ratio | 0.19 | 0.39 |
| Cash ratio | 0.03 | 0.76 |
| Leverage | ||
| Debt / Equity | - | - |
| Debt / Assets | - | - |
| Debt / EBITDA | - | - |
| Interest coverage | -2.4x | -16.4x |
| Equity multiplier | -1.06 | -3.57 |
| Liabilities / Assets | - | - |
| Efficiency | ||
| Asset turnover | 0.92 | 0.47 |
| Inventory turnover | 0.39 | 4.42 |
| Days sales outstanding | 36d | 106d |
| Days inventory outstanding | 943d | 83d |
| Days payable outstanding | - | - |
| Cash conversion cycle | - | - |
| Valuation | ||
| P / E | - | - |
| P / B | - | - |
| P / S | - | - |
| EV / EBITDA | - | - |
| Growth | ||
| Revenue growth (YoY) | -9.8% | - |
| Revenue CAGR (3y) | - | - |
| Revenue CAGR (5y) | - | - |
| Gross profit growth (YoY) | 17.5% | - |
| Operating income growth (YoY) | -79.8% | - |
| Net income growth (YoY) | 0.0% | - |
| EPS growth (YoY) | -1910.0% | - |
| EPS CAGR (3y) | - | - |
| EPS CAGR (5y) | - | - |
| FCF growth (YoY) | - | - |
| FCF CAGR (5y) | - | - |
| Book value growth (YoY) | -55.0% | - |
Stability scores
Piotroski F-score
FY 2022 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✗Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing G Medical Innovations Holdings Ltd. against the 5 most active filers in the same SIC group.